MedTrace Logo

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

NCT00111644 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2016-11-02

No results posted yet for this study

Summary

This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

Conditions

  • Pneumonia, Bacterial

Interventions

DRUG

Ceftriaxone

1000mg iv daily

DRUG

beta-lactam

750mg iv q 23h for 3-14 days

DRUG

beta-lactam

1500mg iv q 12h for 3-14 days

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States
  • Argentina
  • Bulgaria
  • Chile
  • Croatia
  • Hungary
  • Latvia
  • Lithuania
  • Peru
  • Romania
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111644 on ClinicalTrials.gov